Skip to content

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.28
+5.59 (2.53%)
AAPL  275.92
+4.43 (1.63%)
AMD  215.05
+11.27 (5.53%)
BAC  51.93
+0.37 (0.72%)
GOOG  318.47
+18.82 (6.28%)
META  613.05
+18.80 (3.16%)
MSFT  474.00
+1.88 (0.40%)
NVDA  182.55
+3.67 (2.05%)
ORCL  200.28
+1.52 (0.76%)
TSLA  417.78
+26.69 (6.82%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.